Literature DB >> 23047391

Use of dexmedetomidine to prevent pulmonary injury after pneumoperitoneum in ventilated rats.

Sukran Geze1, Bahanur Cekic, Mustafa Imamoğlu, Mehmet Fatih Yörük, Esin Yuluğ, Ahmet Alver, Ahmet Mentese, Engin Ertürk, Mustafa Tusat.   

Abstract

PURPOSE: This study examined the effectiveness of dexmedetomidine in preventing lung injury resulting from pneumoperitoneum in a ventilated rat model.
METHODS: Animals (n=18) were allocated randomly into 3 groups: control group, no pneumoperitoneum; sham group, pneumoperitoneum with intra-abdominal pressure of 12 mm Hg for 60 minutes; and dexmedetomidine group, dexmedetomidine administration 30 minutes before pneumoperitoneum. The rats were rested for 30 minutes after abdominal deflation. Then, blood samples were obtained for plasma malondialdehyde and ischemia-modified albumin (IMA) analyses. Tissue samples were taken for histopathologic examination and malondialdehyde analysis.
RESULTS: Compared with the control group, the sham group had a significantly higher level of plasma IMA. Pretreatment with dexmedetomidine significantly reduced the IMA level. Histopathologically, tissues from sham rats exhibited moderate or severe tissue damage, compared with control tissues. Dexmedetomidine-treated rats showed significantly less tissue damage than sham rats.
CONCLUSIONS: Dexmedetomidine prophylaxis resulted in significantly less IMA production and significantly less neutrophil infiltration, thereby helping to protect the lungs from injury after pneumoperitoneum.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23047391     DOI: 10.1097/SLE.0b013e31826183df

Source DB:  PubMed          Journal:  Surg Laparosc Endosc Percutan Tech        ISSN: 1530-4515            Impact factor:   1.719


  9 in total

1.  Protective effect of dexmedetomidine on intestinal mucosal barrier function in rats after cardiopulmonary bypass.

Authors:  Tong Jia; Zhen Xing; Huijuan Wang And; Guoli Li
Journal:  Exp Biol Med (Maywood)       Date:  2021-12-08

2.  Perioperative "remote" acute lung injury: recent update.

Authors:  Zhaosheng Jin; Ka Chun Suen; Daqing Ma
Journal:  J Biomed Res       Date:  2017-01-19

3.  The MAP2K4/JNK/c-Jun Signaling Pathway Plays A Key Role In Dexmedetomidine Protection Against Acetaminophen-Induced Liver Toxicity.

Authors:  An-Hsun Chou; Chia-Chih Liao; Hung-Chen Lee; Jiin-Tarng Liou; Fu-Chao Liu
Journal:  Drug Des Devel Ther       Date:  2019-11-14       Impact factor: 4.162

4.  Effect and Mechanism of Lidocaine Pretreatment Combined with Dexmedetomidine on Oxidative Stress in Patients with Intracranial Aneurysm Clipping.

Authors:  Junting Zhang; Hongwei Zhang; Liang Zhao; Zhanqi Zhao; Ying Liu
Journal:  J Healthc Eng       Date:  2021-11-24       Impact factor: 2.682

5.  Protective Role of Dexmedetomidine on Ileum and Kidney Damage Caused by Mesenchymal Ischaemia in Rats.

Authors:  Nuray Çakır Sancaktar; Ali Altınbaş; Bahanur Çekiç
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-09-12

6.  Exploration of Potential Molecular Targets of Dexmedetomidine in the Intestinal Repair of Burnt Rats.

Authors:  Chao Qin; Yi Jiang; Mingdong Yu; Yingxue Bian; Yonghao Yu
Journal:  J Inflamm Res       Date:  2021-07-13

7.  Effect of Dexmedetomidine on Postoperative Lung Injury during One-Lung Ventilation in Thoracoscopic Surgery.

Authors:  Jun Meng; Qin Lv; Jiaxiang Yao; Siyu Wang; Kun Yang
Journal:  Biomed Res Int       Date:  2020-10-05       Impact factor: 3.411

8.  Dexmedetomidine protects from post-myocardial ischaemia reperfusion lung damage in diabetic rats.

Authors:  Gülay Kip; Ali Çelik; Mustafa Bilge; Metin Alkan; Hasan Ali Kiraz; Abdullah Özer; Volkan Şıvgın; Özlem Erdem; Mustafa Arslan; Mustafa Kavutçu
Journal:  Libyan J Med       Date:  2015-09-18       Impact factor: 1.743

9.  The Effects of Dexmedetomidine and Ketamine on Oxidative Injuries and Histological Changes Following Blunt Chest Trauma.

Authors:  Seyfi Kartal; Gülay Kip; Ayşegül Küçük; Seyhan Sümeyra Aşçı; Özlem Erdem; Mustafa Arslan; Mustafa Kavutçu
Journal:  Drug Des Devel Ther       Date:  2020-07-23       Impact factor: 4.319

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.